3Caroline S Blaum,Jeffry B Haher. Treatment ofolder adults with diabetes [A] J. In: C. RonaldKahn, George L. King, Alan C. Moses, et al. Jos-fin' s Diabetes Mellitus [ M ]. 14th ed. Boston:r,resbitt Graphics, Inc ,2005 ;737 - 763.
4Rosenstock J, Dailey G, Massi - Benedetti M, etal. Reduced 'hvooglycemia risk with insulinglargine: a m ,a -analysis comparing insulinglargine with human NIH insulin in type 2 dia- betes. Diabetes care ,2005 ;28 (4) :950 - 5.
6Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of insulin - mediathickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke, 2004 ; 35 : 1073 - 1078.
7Muggeo M, Zoppini G; Bonora E, et al. Fast- ing plasma glucose variability predicts 10 - year survival of type 2 diabetic patient. Diabetes Care, 2000;23( 1 ) :45.
3Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26:3080-3086.
4Klonoff DC. Continuous glucose monitoring: roadmap for 21 st century diabetes therapy. Diabetes Care, 2005,28 : 1231-1239.
5Korytkowski M, Thomas A, Reid L. et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care, 2002,25 : 1607-1611.
